Keeping an old friend under control: Regulation of p53 stability

Molecular Medicine Today

Volumn 4, Issue 6, 1998, Pages 250-256

  Kubbutat, Michael H G ^a   Vousden, Karen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

CANCER; CARCINOGENESIS; GENETIC STABILITY; HUMAN; PROTEIN DEGRADATION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031802921     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01260-X     Document Type: Review

References (50)

1. Bates S., Vosuden K.H. p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 6:1996;12-19.
2. Maltzman W., Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4:1984;1689-1694.
3. Kubbutat M.H.G., Vousden K.H. Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies. Semin. Virol. 7:1996;295-304.
4. Beer-Romero P., Glass S., Rolfe M. Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene. 14:1997;595-602.
5. Kubbutat M.H.G., Vousden K.H. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17:1997;460-468.
6. Pariat M.et al. Proteolysis by calpains: a possible contribution to degradation of p53. Mol. Cell. Biol. 17:1997;2806-2815.
7. Gonen H.et al. On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett. 406:1997;17-22.
8. Sorimachi H., Ishiura S., Suzuki K. Structure and physiological function of calpains. Biochem. J. 328:1997;721-732.
9. Zhang W., Lu Q., Xie Z.J., Mellgren R.L. Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. Oncogene. 14:1997;255-263.
10. Molinari M., Okorokov A.L., Milner J. Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa fragments competent for sequence-specific DNA binding. Oncogene. 13:1996;2077-2086.
11. Okorokov A.L., Ponchel F., Milner J. Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53. EMBO J. 16:1997;6008-6017.
12. Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:1993;461-468.
13. Momand J., Zambetti G.P., George D.L., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
14. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 378:1995;203-206.
15. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature. 378:1995;206-208.
16. Kubbutat M.H.G., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
17. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
18. Bottger A.et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7:1997;860-869.
19. Vojtesek B., Lane D.P. Regulation of p53 protein expression in human breast cancer cell lines. J. Cell Sci. 105:1993;607-612.
20. Midgley C.A., Lane D.P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 15:1997;1179-1189.
21. Henning W.et al. MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. J. Virol. 71:1997;7609-7618.
22. Siliciano J.D.et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:1997;3471-3481.
23. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
24. Mayo L.D., Turchi J.J., Berberich S.J. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57:1997;5013-5016.
25. Huang L., Clarkin K.C., Wahl G.M. p53-dependent cell cycle arrests are preserved in DNA-activated protein kinase-deficient mouse fibroblasts. Cancer Res. 56:1996;2940-2944.
26. Rathmell W.K.et al. DNA-dependent protein kinase is not required for accumulation of p53 of cell cycle arrest after DNA damage. Cancer Res. 57:1997;68-74.
27. Kastan M.B.et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
28. Xu Y., Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev. 10:1996;2401-2410.
29. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
30. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
31. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppressor pathways. Cell. 92:1998;725-734.
32. Hupp T.R., Sparks A., Lane D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 83:1995;237-245.
33. Jayaraman J., Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell. 81:1995;1021-1029.
34. Lee S., Elenbaas B., Levine A., Griffith J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell. 81:1995;1013-1020.
35. Jayaraman L.et al. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 11:1997;558-570.
36. Lutzker S.G., Levine A.J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat. Med. 2:1996;804-810.
37. waf1/cip1. Carcinogenesis. 18:1997;2313-2318.
38. Middeler G.et al. The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene. 14:1997;1407-1417.
39. Moll U.M.et al. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16:1996;1126-1137.
40. Roth J.et al. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:1998;554-564.
41. Fu L., Minden M.D., Benchimol S. Translational regulation of human p53 gene expression. EMBO J. 15:1996;4392-4401.
42. Fu L., Benchimol S. Participation of the human p53 3′UTR in translational repression and activation following gamma-irradiation. EMBO J. 16:1997;4117-4125.
43. Mosner J.et al. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 14:1995;4442-4449.
44. Srivistava S.et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 348:1990;747-749.
45. Malkin D.et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasias. Science. 250:1990;1233-1238.
46. Selivanova G.et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3:1997;632-638.
47. Marston N.J., Crook T., Vousden K.H. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene. 9:1994;2707-2716.
48. Moll U.M., Riou G., Levine A.J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. U. S. A. 89:1992;7262-7266.
49. Oliner J.D.et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83.
50. Crook T.et al. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet. 339:1992;1070-1073.